Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 31,249 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Dianthus Therapeutics Trading Up 1.1%

Shares of NASDAQ:DNTH opened at $98.64 on Tuesday. The stock has a market capitalization of $5.39 billion, a PE ratio of -23.88 and a beta of 1.20. Dianthus Therapeutics, Inc. has a 1 year low of $18.08 and a 1 year high of $102.33. The firm has a fifty day moving average price of $87.98 and a 200 day moving average price of $72.34.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Handelsbanken Fonder AB bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $1,491,000. Assenagon Asset Management S.A. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at about $27,358,000. Seven Fleet Capital Management LP lifted its stake in shares of Dianthus Therapeutics by 451.6% in the first quarter. Seven Fleet Capital Management LP now owns 80,809 shares of the company’s stock valued at $6,781,000 after buying an additional 66,158 shares during the period. DV Trading LLC bought a new stake in shares of Dianthus Therapeutics in the first quarter valued at about $2,228,000. Finally, Glenmede Trust Co. NA lifted its stake in shares of Dianthus Therapeutics by 96.5% in the first quarter. Glenmede Trust Co. NA now owns 12,470 shares of the company’s stock valued at $1,046,000 after buying an additional 6,125 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DNTH has been the topic of several analyst reports. Wedbush increased their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. William Blair reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.